PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

分组1 - PTC Therapeutics reported a quarterly loss of $1.67 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.21, representing an earnings surprise of -700.58% [1] - The company posted revenues of $164.68 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 45.96%, compared to year-ago revenues of $213.17 million [2] - PTC Therapeutics shares have underperformed the market, losing about 9.3% since the beginning of the year, while the S&P 500 gained 0.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is -$0.58 on revenues of $206 million, and for the current fiscal year, it is -$1.60 on revenues of $959.42 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Ovid Therapeutics, another company in the same industry, is expected to report a quarterly loss of $0.10 per share, with revenues projected to be $0.24 million, reflecting a year-over-year increase of 203.8% [9]